Metiltestosteron etkileşimleri

These drugs include, but are not limited to, the following: the anticonvulsants carbamazepine, oxcarbazepine, phenobarbital, phenytoin the androgen receptor inhibitor enzalutamide the antimycobacterials rifampin, rifapentine the cytotoxic agent mitotane St. (Doravirin etiketi, Kontrendikasyonlar)

Because of the ability of Type II 5α-reductase inhibitors to inhibit the conversion of testosterone to 5α-dihydrotestosterone (DHT), finasteride may cause abnormalities of the external genitalia of a male fetus of a pregnant female who receives finasteride. (Finasterid etiketi, Kontrendikasyonlar)

CONTRAINDICATIONS: Precocious puberty, prostatic carcinoma or other androgen-dependent neoplasm, prior allergic reaction to HCG. (Koryonik gonadotropin etiketi, Kontrendikasyonlar)

To date, epidemiologic studies and randomized controlled trials have been inconclusive for determining the risk of major adverse cardiovascular events (MACE), such as non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death, with the use of testosterone compared to non-use. (Metiltestosteron etiketi, Uyarılar)

DRUG INTERACTIONS Anticoagulants: C-17 substituted derivatives of testosterone, such as methandrostenolone, have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants. (Metiltestosteron etiketi, İlaç etkileşimleri)

DRUG INTERACTIONS Anticoagulants: C-17 substituted derivatives of testosterone, such as methandrostenolone, have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants. (Metiltestosteron etiketi, İlaç etkileşimleri)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (Metiltestosteron etiketi, Uyarılar)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (Metiltestosteron etiketi, Uyarılar)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (Metiltestosteron etiketi, Uyarılar)

DRUG INTERACTIONS Anticoagulants: C-17 substituted derivatives of testosterone, such as methandrostenolone, have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants. (Metiltestosteron etiketi, İlaç etkileşimleri)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (Metiltestosteron etiketi, Uyarılar)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (Metiltestosteron etiketi, Uyarılar)

DRUG INTERACTIONS Anticoagulants: C-17 substituted derivatives of testosterone, such as methandrostenolone, have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants. (Metiltestosteron etiketi, İlaç etkileşimleri)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (Metiltestosteron etiketi, Uyarılar)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (Metiltestosteron etiketi, Uyarılar)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (Metiltestosteron etiketi, Uyarılar)

DRUG INTERACTIONS Anticoagulants: C-17 substituted derivatives of testosterone, such as methandrostenolone, have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants. (Metiltestosteron etiketi, İlaç etkileşimleri)

DRUG INTERACTIONS Anticoagulants: C-17 substituted derivatives of testosterone, such as methandrostenolone, have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants. (Metiltestosteron etiketi, İlaç etkileşimleri)

Free hormone concentrations, such as testosterone and estradiol, may be decreased. (Estradiol ve noretisteron etiketi, Uyarılar ve önlemler)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (Metiltestosteron etiketi, Uyarılar)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (Metiltestosteron etiketi, Uyarılar)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (Metiltestosteron etiketi, Uyarılar)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (Metiltestosteron etiketi, Uyarılar)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (Metiltestosteron etiketi, Uyarılar)

For Men : Clinical monitoring for spermatogenesis utilizes the following indirect or direct measures: Serum testosterone level Semen analysis 5.11 FOLLISTIM Pen The FOLLISTIM Pen is intended only for use with FOLLISTIM AQ Cartridge. (Follitropin etiketi, Uyarılar ve önlemler)

DRUG INTERACTIONS Anticoagulants: C-17 substituted derivatives of testosterone, such as methandrostenolone, have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants. (Metiltestosteron etiketi, İlaç etkileşimleri)

…medications, pramlintide acetate, insulin, angiotensin converting enzyme (ACE) inhibitors, H 2 receptor antagonists, fibrates, propoxyphene, pentoxifylline, somatostatin analogs, anabolic steroids and androgens, cyclophosphamide, phenyramidol, guanethidine, fluconazole, sulfinpyrazone, tetracyclines, clarithromycin, disopyramide, quinolones, and those drugs… (Glimepirid etiketi, İlaç etkileşimleri)

Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT interval. (Goserelin etiketi, Uyarılar ve önlemler)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (Metiltestosteron etiketi, Uyarılar)

DRUG INTERACTIONS Anticoagulants: C-17 substituted derivatives of testosterone, such as methandrostenolone, have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants. (Metiltestosteron etiketi, İlaç etkileşimleri)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (Metiltestosteron etiketi, Uyarılar)

Insulin: In diabetic patients the metabolic effects of androgens may decrease blood glucose and insulin requirements. (Metiltestosteron etiketi, İlaç etkileşimleri)

Insulin: In diabetic patients the metabolic effects of androgens may decrease blood glucose and insulin requirements. (Metiltestosteron etiketi, İlaç etkileşimleri)

Insulin: In diabetic patients the metabolic effects of androgens may decrease blood glucose and insulin requirements. (Metiltestosteron etiketi, İlaç etkileşimleri)

Insulin: In diabetic patients the metabolic effects of androgens may decrease blood glucose and insulin requirements. (Metiltestosteron etiketi, İlaç etkileşimleri)

Insulin: In diabetic patients the metabolic effects of androgens may decrease blood glucose and insulin requirements. (Metiltestosteron etiketi, İlaç etkileşimleri)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (Metiltestosteron etiketi, Uyarılar)

Free hormone concentrations, such as testosterone and estradiol, may be decreased. (Konjuge östrojenler etiketi, Önlemler)

Free hormone concentrations, such as testosterone and estradiol, may be decreased. (Konjuge östrojenler ve bazedoksifen etiketi, Uyarılar ve önlemler)

PRECAUTIONS General Induction of androgen secretion by hCG may cause fluid retention. (Koriogonadotropin alfa etiketi, Önlemler)

Androgens/Anabolic Steroids Asparaginase Glucocorticoids Slow-Release Nictonic Acid These drugs may decrease serum TBG concentration. (Levotiroksin etiketi, İlaç etkileşimleri)

Androgens/Anabolic Steroids Asparaginase Glucocorticoids Slow-Release Nicotinic Acid These drugs may decrease serum TBG concentration. (Liyotironin etiketi, İlaç etkileşimleri)

However, clinical studies have shown that lovastatin does not reduce basal plasma cortisol concentration or impair adrenal reserve, and does not reduce basal plasma testosterone concentration. (Lovastatin etiketi, İlaç etkileşimleri)

Tumor Flare: Increased serum testosterone (~ 50% above baseline) may occur when initiating treatment with LUPRON DEPOT. (Löprolid etiketi, Uyarılar ve önlemler)

The following laboratory tests may be affected by progestins including MPA Injectable Suspension, USP: (a) Plasma and urinary steroid levels are decreased (e.g., progesterone, estradiol, pregnanediol, testosterone, cortisol). (Medroksiprogesteron etiketi, İlaç etkileşimleri)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (Metiltestosteron etiketi, Uyarılar)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (Metiltestosteron etiketi, Uyarılar)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (Metiltestosteron etiketi, Uyarılar)

…anti-diabetic medications, pramlintide acetate, insulin, angiotensin converting enzyme (ACE) inhibitors, H2 receptor antagonists, fibrates, propoxyphene, pentoxifylline, somatostatin analogs, anabolic steroids and androgens, cyclophosphamide, phenyramidol, guanethidine, fluconazole, sulfinpyrazone, tetracyclines, clarithromycin, disopyramide, quinolones, and those drugs… (Pioglitazon ve glimepirid etiketi, İlaç etkileşimleri)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (Metiltestosteron etiketi, Uyarılar)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (Metiltestosteron etiketi, Uyarılar)

Reproductive effects: Include decreased testosterone and increased prolactin levels. (Ramelteon etiketi, Uyarılar ve önlemler)

Insulin: In diabetic patients the metabolic effects of androgens may decrease blood glucose and insulin requirements. (Metiltestosteron etiketi, İlaç etkileşimleri)

DRUG INTERACTIONS Anticoagulants: C-17 substituted derivatives of testosterone, such as methandrostenolone, have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants. (Metiltestosteron etiketi, İlaç etkileşimleri)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (Metiltestosteron etiketi, Uyarılar)

Abiraterone: Spironolactone binds to the androgen receptor and may increase prostate‑specific antigen (PSA) levels in abiraterone-treated prostate cancer patients. (Spironolakton ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Hypercalcemia in Patients with Metastatic Breast Cancer As with other additive hormonal therapy (estrogens and androgens), hypercalcemia has been reported in some breast cancer patients with bone metastases within a few weeks of starting treatment with tamoxifen. (Tamoksifen etiketi, Uyarılar ve önlemler)

Insulin: In diabetic patients the metabolic effects of androgens may decrease blood glucose and insulin requirements. (Metiltestosteron etiketi, İlaç etkileşimleri)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (Metiltestosteron etiketi, Uyarılar)

Tumor Flare: Transient increase in serum testosterone levels can occur within the first few weeks of treatment. (Triptorelin etiketi, Uyarılar ve önlemler)

DRUG INTERACTIONS Anticoagulants: C-17 substituted derivatives of testosterone, such as methandrostenolone, have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants. (Metiltestosteron etiketi, İlaç etkileşimleri)

In addition to discontinuation of the drug, diuretic therapy may be required. (Metiltestosteron etiketi, Uyarılar)

In addition to discontinuation of the drug, diuretic therapy may be required. (Metiltestosteron etiketi, Uyarılar)

In addition to discontinuation of the drug, diuretic therapy may be required. (Metiltestosteron etiketi, Uyarılar)

In addition to discontinuation of the drug, diuretic therapy may be required. (Metiltestosteron etiketi, Uyarılar)

In addition to discontinuation of the drug, diuretic therapy may be required. (Metiltestosteron etiketi, Uyarılar)

In addition to discontinuation of the drug, diuretic therapy may be required. (Metiltestosteron etiketi, Uyarılar)

In addition to discontinuation of the drug, diuretic therapy may be required. (Metiltestosteron etiketi, Uyarılar)

In addition to discontinuation of the drug, diuretic therapy may be required. (Metiltestosteron etiketi, Uyarılar)

In addition to discontinuation of the drug, diuretic therapy may be required. (Metiltestosteron etiketi, Uyarılar)

In addition to discontinuation of the drug, diuretic therapy may be required. (Metiltestosteron etiketi, Uyarılar)

In addition to discontinuation of the drug, diuretic therapy may be required. (Metiltestosteron etiketi, Uyarılar)

In addition to discontinuation of the drug, diuretic therapy may be required. (Metiltestosteron etiketi, Uyarılar)

In addition to discontinuation of the drug, diuretic therapy may be required. (Metiltestosteron etiketi, Uyarılar)

In addition to discontinuation of the drug, diuretic therapy may be required. (Metiltestosteron etiketi, Uyarılar)

In addition to discontinuation of the drug, diuretic therapy may be required. (Metiltestosteron etiketi, Uyarılar)

In addition to discontinuation of the drug, diuretic therapy may be required. (Metiltestosteron etiketi, Uyarılar)

In addition to discontinuation of the drug, diuretic therapy may be required. (Metiltestosteron etiketi, Uyarılar)

In addition to discontinuation of the drug, diuretic therapy may be required. (Metiltestosteron etiketi, Uyarılar)

Free thyroid hormone levels remain unchanged, however, and there is no clinical evidence of thyroid dysfunction. (Metiltestosteron etiketi, Önlemler)

In addition to discontinuation of the drug, diuretic therapy may be required. (Metiltestosteron etiketi, Uyarılar)

In addition to discontinuation of the drug, diuretic therapy may be required. (Metiltestosteron etiketi, Uyarılar)

Free thyroid hormone levels remain unchanged, however, and there is no clinical evidence of thyroid dysfunction. (Metiltestosteron etiketi, Önlemler)

In addition to discontinuation of the drug, diuretic therapy may be required. (Metiltestosteron etiketi, Uyarılar)

In addition to discontinuation of the drug, diuretic therapy may be required. (Metiltestosteron etiketi, Uyarılar)

In addition to discontinuation of the drug, diuretic therapy may be required. (Metiltestosteron etiketi, Uyarılar)

In addition to discontinuation of the drug, diuretic therapy may be required. (Metiltestosteron etiketi, Uyarılar)

Free thyroid hormone levels remain unchanged, however, and there is no clinical evidence of thyroid dysfunction. (Metiltestosteron etiketi, Önlemler)

In addition to discontinuation of the drug, diuretic therapy may be required. (Metiltestosteron etiketi, Uyarılar)

In addition to discontinuation of the drug, diuretic therapy may be required. (Metiltestosteron etiketi, Uyarılar)

Free thyroid hormone levels remain unchanged, however, and there is no clinical evidence of thyroid dysfunction. (Metiltestosteron etiketi, Önlemler)

In addition to discontinuation of the drug, diuretic therapy may be required. (Metiltestosteron etiketi, Uyarılar)

In addition to discontinuation of the drug, diuretic therapy may be required. (Metiltestosteron etiketi, Uyarılar)

In addition to discontinuation of the drug, diuretic therapy may be required. (Metiltestosteron etiketi, Uyarılar)

In addition to discontinuation of the drug, diuretic therapy may be required. (Metiltestosteron etiketi, Uyarılar)